# US 2022/0033845 A1 · Expression vectors for eukaryotic expression systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033845 A1
- Document ID: US20220033845A1
- Status: Published application
- Kind: A1
- Application number: 17/277,663
- Filed: 2019-09-23
- Published: 2022-02-03
- Earliest claimed: 2018-09-24
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Zhimei Du; Bo Jiang; Xiaoyan Tang
- Web page: https://patentgrep.com/patent/US20220033845A1

## CPC

- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/85: for animal cells
- C07K 16/06: from serum
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C12N 2510/02: Cells for production
- C12N 2800/90: Vectors containing a transposable element
- C12N 2820/55: from bacteria
- C12N 2830/40: being an insulator
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides expression vectors for expressing recombinant proteins (e.g., biologics) in mammalian cells. Also provided are host cells comprising the expression vectors, methods of producing the recombinant proteins, and methods of propagating the expression vectors.

## Claims

### Claim at position 1

1-71. (canceled)

### Claim 72

An expression vector comprising:
(a) a first expression cassette comprising the following elements in the order of upstream to downstream: a promoter operably linked to an insertion site for a gene of interest (GOI), an internal ribosome entry site (IRES), a polynucleotide encoding a eukaryotic selectable marker, and a polyadenylation (polyA) signal;
(b) a second expression cassette comprising a polynucleotide encoding a bacterial selectable marker; and
(c) a bacterial plasmid origin of replication;
wherein optionally the first expression cassette further comprises one or more regulatory element; and
wherein optionally the regulatory element is an enhancer, an insulator, a locus control region (LCR), a matrix attachment region (MAR), a scaffold attachment region (SAR), an expression augmenting sequence element (EASE), an adenovirus tripartite leader (TPL), or a ubiquitous chromatin opening element (UCOE).

### Claim 73 (depends on 72)

The expression vector of claim 72, further comprising two inverted terminal repeat (ITR) sequences flanking the first expression cassette; wherein optionally the ITR is piggyBac ITR.

### Claim 74 (depends on 73)

The expression vector of claim 73, wherein
(a) the IRES comprises a polynucleotide sequence of SEQ ID NO:1, 2, 3, 23, 24, or 25;
(b) the eukaryotic selectable marker is a neomycin phosphotransferase, a histidinol dehydrogenase, a hygromycin B phosphotransferase, a xanthine-guanine phosphoribosyltransferase, a dihydrofolate reductase, a tryptophan synthetase, a puromycin N-acetyl-transferase, a thymidine kinase, an adenine phosphoribosyl transferase, a glutamine synthetase, an adenosine deaminase, or metallothionein-1; wherein optionally the eukaryotic selectable marker is a glutamine synthetase or a neomycin phosphotransferase;
(c) the promoter is a human cytomegalovirus (CMV) immediate-early promoter, a human elongation factor 1 alpha (EF1a) promoter, a SV40 promoter, a phosphoglycerate kinase 1 (PGK1) promoter, a human ubiquitin C (Ubc) promoter, a human β-actin promoter, a CAG promoter, a yeast transcription elongation factor 1 (TEF1) promoter, a yeast glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter, or a yeast alcohol dehydrogenase 1 (ADH1) promoter; wherein optionally the promoter is a human CMV immediate-early promoter;
(d) the enhancer is a CMV immediate-early enhancer; and/or
(e) the insulator is HS4.

### Claim 75 (depends on 74)

The expression vector of claim 74, wherein the IRES comprises a polynucleotide sequence of SEQ ID NO:3.

### Claim 76 (depends on 74)

The expression vector of claim 74, wherein the IRES comprises a polynucleotide sequence of SEQ ID NO:25.

### Claim 77

An expression vector comprising:
(a) a first expression cassette comprising the following elements in the order of upstream to downstream: a first insulator, an EASE, a promoter, a TPL, an insertion site for a GOI, an IRES, a polynucleotide encoding a eukaryotic selectable marker, a polyA signal, and a second insulator;
(b) two ITR sequences flanking the first expression cassette;
(c) a second expression cassette comprising a polynucleotide encoding a bacterial selectable marker; and
(d) a bacterial plasmid origin of replication;
wherein optionally the first expression cassette further comprises an enhancer;
wherein optionally the enhancer is located between the EASE and the promoter;
wherein optionally the enhancer is a human CMV immediate-early enhancer;
wherein optionally the promoter is a human CMV immediate-early promoter;
wherein optionally the first and the second insulators are HS4;
wherein optionally the ITR is piggyBac ITR;
wherein optionally the eukaryotic selectable marker is a glutamine synthetase or a neomycin phosphotransferase; and
wherein optionally the IRES comprises a polynucleotide sequence of SEQ ID NO:1, 2, 3, 23, 24, or 25.

### Claim 78 (depends on 77)

The expression vector of claim 77, wherein the IRES comprises a polynucleotide sequence of SEQ ID NO:3.

### Claim 79 (depends on 77)

The expression vector of claim 77, wherein the IRES comprises a polynucleotide sequence of SEQ ID NO:25.

### Claim 80

An expression vector,
(a) comprising a polynucleotide sequence of SEQ ID NO:4, 5, 6, 7, 8, 26, 27, 28, or 29;
(b) consisting of a polynucleotide sequence of SEQ ID NO:4, 5, 6, 7, 8, 26, 27, 28, or 29; or
(c) consisting essentially of a polynucleotide sequence of SEQ ID NO:4, 5, 6, 7, 8, 26, 27, 28, or 29.

### Claim 81 (depends on 80)

The expression vector of claim 80, wherein the polynucleotide sequence is SEQ ID NO:7.

### Claim 82 (depends on 80)

The expression vector of claim 80, wherein the polynucleotide sequence is SEQ ID NO:8.

### Claim 83 (depends on 80)

The expression vector of claim 80, wherein the polynucleotide sequence is SEQ ID NO:27.

### Claim 84 (depends on 80)

The expression vector of claim 80, wherein the polynucleotide sequence is SEQ ID NO:29.

### Claim 85 (depends on 78)

The expression vector of claim 78, wherein the first expression cassette further comprises the GOI encoding
(a) a therapeutic or prophylactic protein;
(b) a light chain of a monoclonal antibody or fragments thereof; or
(c) a heavy chain of a monoclonal antibody or fragments thereof.

### Claim 86 (depends on 85)

A host cell comprising the expression vector of claim 85, wherein optionally the host cell is a mammalian host cell or a bacterial host cell; wherein optionally the mammalian host cell is a CHO cell; and wherein optionally the endogenous glutamine synthetase gene of the CHO cell is knocked out.

### Claim 87 (depends on 86)

A method of producing a polypeptide encoded by a GOI, comprising culturing the host cell of claim 86 under conditions in which the polypeptide is expressed, wherein the expression vector comprises the GOI encoding the polypeptide; and wherein the method further comprises recovering the polypeptide from the culture.

### Claim 88 (depends on 86)

A method of propagating an expression vector, comprising culturing the host cell of claim 86 under conditions in which the expression vector is replicated; and wherein optionally the method further comprises recovering the expression vector from the culture.

### Claim 89 (depends on 78)

A host cell comprising a first expression vector of claim 78 and a second expression vector of claim 78, wherein the first expression vector further comprises a first GOT encoding a light chain of a monoclonal antibody or fragments thereof; the second expression vector further comprises a second GOI encoding a heavy chain of the monoclonal antibody or fragments thereof; and wherein the eukaryotic selectable marker of the first expression vector is different from the eukaryotic selectable marker of the second expression vector.

### Claim 90 (depends on 89)

A method of producing a monoclonal antibody, comprising culturing the host cell of claim 89 under conditions in which the light chain of the monoclonal antibody and the heavy chain of the monoclonal antibody are expressed; wherein optionally the method further comprises recovering the monoclonal antibody from the culture.
